$2.26-0.07 (-2.80%)
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
CDT Equity Inc. in the Healthcare sector is trading at $2.26. The stock is currently near its 52-week low of $2.20, remaining 97.8% below its 200-day moving average. Technical signals show oversold RSI of 3 and bullish MACD crossover, explaining why CDT maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has co...